HeartBeam (NASDAQ: BEAT) announced its synthesized 12-lead ECG met clinical endpoints in the VALID-ECG pivotal study, achieving 93.4% diagnostic agreement with standard ECGs for arrhythmia assessment.

Data demonstrated a 93.4% overall diagnostic agreement. That indicated that HeartBeam’s 12-lead ECG can support the diagnosis of arrhythmias in a manner consistent with standard 12-lead ECGs.

This paper investigates the design of both hardware and software for a 12-lead mobile electrocardiogram (ECG) monitoring system. The 12-lead ECG captures the heart's electrical activity from multiple ...

One of the most vital parts of the electrocardiogram (ECG) is the QRS complex. It is considered as an essential basis for determination of heart condition. Since the nature of an ECG signal is non ...

The British publisher Tilted Axis specialized in innovative translated literature. It won them major awards. Now they’re coming to the U.S. By Alexandra Alter A few years ago, the translator ...

The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient’s 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes.

The FDA cleared the AliveCor 12-lead ECG system midway through last year. CMS assigned the AI-powered technology to Ambulatory Payment Classification (APC) 5733.

MOUNTAIN VIEW, Calif., Jan. 14, 2025 /PRNewswire/ -- AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today announced new data published in Computing in ...

Just a quarter teaspoon of any of those products has more lead than you should consume in an entire day, says James Rogers, PhD, the director of food safety research and testing at CR. “If you ...

The VALID-ECG study will be a component of HeartBeam’s subsequent 510 (k) submission, which will focus on the algorithms that take the 3D VECG signal and synthesize a 12-lead ECG, providing ...